Karyopharm Therapeutics Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Karyopharm Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KPTI, but not buy additional shares or sell existing shares.
View analyst ratings for Karyopharm Therapeutics or view top-rated stocks.

6 Wall Street analysts have issued 1 year price objectives for Karyopharm Therapeutics' shares. Their KPTI stock forecasts range from $6.00 to $22.00. On average, they predict Karyopharm Therapeutics' stock price to reach $11.57 in the next year. This suggests a possible upside of 123.8% from the stock's current price.
View analysts' price targets for Karyopharm Therapeutics or view top-rated stocks among Wall Street analysts.

Karyopharm Therapeutics' stock was trading at $6.43 at the start of the year. Since then, KPTI stock has decreased by 19.6% and is now trading at $5.17.
View the best growth stocks for 2022 here.

Karyopharm Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Karyopharm Therapeutics.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) posted its earnings results on Thursday, May, 5th. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.63) by $0.10. The firm had revenue of $47.67 million for the quarter, compared to analyst estimates of $34.78 million. During the same period in the previous year, the company posted ($0.77) EPS.
View Karyopharm Therapeutics' earnings history.

31 employees have rated Karyopharm Therapeutics CEO Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among Karyopharm Therapeutics' employees.

Some companies that are related to Karyopharm Therapeutics include Aurinia Pharmaceuticals (AUPH), Xencor (XNCR), Amphastar Pharmaceuticals (AMPH), Dynavax Technologies (DVAX), Travere Therapeutics (TVTX), Supernus Pharmaceuticals (SUPN), Ligand Pharmaceuticals (LGND), Cryoport (CYRX), Madrigal Pharmaceuticals (MDGL), Taro Pharmaceutical Industries (TARO), BridgeBio Pharma (BBIO), Sierra Oncology (SRRA), BELLUS Health (BLUSF), Myovant Sciences (MYOV) and Day One Biopharmaceuticals (DAWN).
View all of KPTI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY).

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Karyopharm Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include State Street Corp (13.81%), BlackRock Inc. (9.98%), Palo Alto Investors LP (7.08%), Vanguard Group Inc. (4.99%), Rice Hall James & Associates LLC (1.69%) and Rice Hall James & Associates LLC (1.69%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Deepika Pakianathan, Garen G Bohlin, Jatin Shah, John Demaree, Mansoor Raza Mirza, Michael Kauffman, Michael Mason, Ran Frenkel, Richard A Paulson, Sharon Shacham, Sohanya Roshan Cheng, Stephen Mitchener and Tanya Lewis.
View institutional ownership trends for Karyopharm Therapeutics.

KPTI stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Frontier Capital Management Co. LLC, Citigroup Inc., Group One Trading L.P., Simplex Trading LLC, Dupont Capital Management Corp, Allianz Asset Management GmbH, and Rhumbline Advisers. Company insiders that have sold Karyopharm Therapeutics company stock in the last two years include Christopher Brett Primiano, Deepika Pakianathan, Jatin Shah, Mansoor Raza Mirza, Michael Kauffman, Michael Mason, Richard A Paulson, Sharon Shacham, Sohanya Roshan Cheng, Stephen Mitchener, and Tanya Lewis.
View insider buying and selling activity for Karyopharm Therapeutics or view top insider-selling stocks.

KPTI stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Bank of America Corp DE, Vanguard Group Inc., Acadian Asset Management LLC, Candriam Luxembourg S.C.A., UBS Group AG, Victory Capital Management Inc., and Palo Alto Investors LP. Company insiders that have bought Karyopharm Therapeutics stock in the last two years include Garen G Bohlin, Jatin Shah, and John Demaree.
View insider buying and selling activity for Karyopharm Therapeutics or or view top insider-buying stocks.

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KPTI stock can currently be purchased for approximately $5.17.

Karyopharm Therapeutics (NASDAQ:KPTI) has a market capitalization of $410.60 million and generates $209.82 million in revenue each year. The company earns $-124.09 million in net income (profit) each year or ($1.470010) on an earnings per share basis.

Karyopharm Therapeutics employs 442 workers across the globe.

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The official website for Karyopharm Therapeutics is www.karyopharm.com. The company can be reached via phone at (617) 658-0600 or via email at [email protected].